Please login to the form below

Not currently logged in
Email:
Password:

cost-effectiveness

This page shows the latest cost-effectiveness news and features for those working in and with pharma, biotech and healthcare.

Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness

Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness

Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness. ... data, making it hard for it to come to clear conclusions about their cost effectiveness.

Latest news

More from news
Approximately 3 fully matching, plus 552 partially matching documents found.

Latest Intelligence

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Bluebird is strongly advocating an annuity-type approach – where instead of having to pay the whole cost upfront, payers can pay off the bill in yearly instalments. ... Raju Prasad says Bluebird can offer a compelling cost-effectiveness case for its

  • Shaping healthcare Shaping healthcare

    It’s a huge challenge. Germany and France aren’t easy either. They don’t do the cost-effectiveness approach, at least not with the same consequences as the UK, but ... their therapeutic effectiveness approaches also lead to very difficult

  • No incentive for a cure No incentive for a cure

    In August 2017, Novartis announced that Kymriah would be $475, 000 per treatment, which caused a lot of headlines, but was actually lower than many analysts were expecting; a cost-effectiveness ... Indeed, the cost-effectiveness evidence for many

  • Public relations

    Healthcare terms - Public relations.

  • Digital

    Healthcare terms - Digital.

More from intelligence
Approximately 0 fully matching, plus 52 partially matching documents found.

Latest appointments

  • Former NICE chair joins board of biotech Former NICE chair joins board of biotech

    The former chair of England's cost-effectiveness body for medicines, Sir Michael Rawlins, has made a contentious move to the US biotech Intra-Cellular Therapies as member of its board ... His expertise in the cost-effectiveness of new pharmaceuticals and

  • Executive changes at Teva as community and institutional affairs division launched

    Referencing Teva's previous record in compliance, Dr De Notaristefani said: “ We will continue this practice as we begin to set the industry standard for regulatory compliance, customer service and cost ... effectiveness.”. Teva launches community

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics